nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0257	0.0433	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0257	0.0433	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0222	0.0374	CbGbCtD
Aripiprazole—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0222	0.0374	CbGbCtD
Aripiprazole—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0215	0.0363	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0215	0.0363	CbGbCtD
Aripiprazole—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0213	0.0359	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0195	0.0328	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0195	0.0328	CbGbCtD
Aripiprazole—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0195	0.0328	CbGbCtD
Aripiprazole—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0195	0.0328	CbGbCtD
Aripiprazole—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0193	0.0325	CbGbCtD
Aripiprazole—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0193	0.0325	CbGbCtD
Aripiprazole—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0166	0.028	CbGbCtD
Aripiprazole—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0161	0.0272	CbGbCtD
Aripiprazole—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0146	0.0246	CbGbCtD
Aripiprazole—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0146	0.0246	CbGbCtD
Aripiprazole—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0139	0.0234	CbGbCtD
Aripiprazole—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0139	0.0234	CbGbCtD
Aripiprazole—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0131	0.022	CbGbCtD
Aripiprazole—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0131	0.022	CbGbCtD
Aripiprazole—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0125	0.0211	CbGbCtD
Aripiprazole—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0118	0.0199	CbGbCtD
Aripiprazole—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0118	0.0199	CbGbCtD
Aripiprazole—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0108	0.0182	CbGbCtD
Aripiprazole—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0105	0.0177	CbGbCtD
Aripiprazole—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0102	0.0172	CbGbCtD
Aripiprazole—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0099	0.0167	CbGbCtD
Aripiprazole—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0095	0.016	CbGbCtD
Aripiprazole—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0095	0.016	CbGbCtD
Aripiprazole—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00911	0.0154	CbGbCtD
Aripiprazole—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00896	0.0151	CbGbCtD
Aripiprazole—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00896	0.0151	CbGbCtD
Aripiprazole—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00884	0.0149	CbGbCtD
Aripiprazole—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00831	0.014	CbGbCtD
Aripiprazole—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00831	0.014	CbGbCtD
Aripiprazole—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00751	0.0127	CbGbCtD
Aripiprazole—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00751	0.0127	CbGbCtD
Aripiprazole—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00705	0.0119	CbGbCtD
Aripiprazole—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00649	0.0109	CbGbCtD
Aripiprazole—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0063	0.0106	CbGbCtD
Aripiprazole—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00569	0.0096	CbGbCtD
Aripiprazole—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00569	0.0096	CbGbCtD
Aripiprazole—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00546	0.0092	CbGbCtD
Aripiprazole—H1F0—semen—acquired immunodeficiency syndrome	0.00378	0.0536	CbGeAlD
Aripiprazole—DRD1—nerve—acquired immunodeficiency syndrome	0.0018	0.0255	CbGeAlD
Aripiprazole—HTR3A—nerve—acquired immunodeficiency syndrome	0.00173	0.0247	CbGeAlD
Aripiprazole—HTR7—nerve—acquired immunodeficiency syndrome	0.00112	0.016	CbGeAlD
Aripiprazole—DRD2—nerve—acquired immunodeficiency syndrome	0.00106	0.0151	CbGeAlD
Aripiprazole—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.001	0.0142	CbGeAlD
Aripiprazole—HTR7—endothelium—acquired immunodeficiency syndrome	0.000956	0.0136	CbGeAlD
Aripiprazole—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.000888	0.0126	CbGeAlD
Aripiprazole—HTR7—blood plasma—acquired immunodeficiency syndrome	0.000849	0.0121	CbGeAlD
Aripiprazole—CHRM5—skin of body—acquired immunodeficiency syndrome	0.000767	0.0109	CbGeAlD
Aripiprazole—H1F0—retina—acquired immunodeficiency syndrome	0.000753	0.0107	CbGeAlD
Aripiprazole—HTR2A—nerve—acquired immunodeficiency syndrome	0.0007	0.00995	CbGeAlD
Aripiprazole—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.000692	0.00984	CbGeAlD
Aripiprazole—HTR1E—nervous system—acquired immunodeficiency syndrome	0.000692	0.00983	CbGeAlD
Aripiprazole—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.000666	0.00947	CbGeAlD
Aripiprazole—H1F0—skin of body—acquired immunodeficiency syndrome	0.000661	0.0094	CbGeAlD
Aripiprazole—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000653	0.00928	CbGeAlD
Aripiprazole—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.000623	0.00885	CbGeAlD
Aripiprazole—DRD4—brain—acquired immunodeficiency syndrome	0.000614	0.00872	CbGeAlD
Aripiprazole—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000607	0.00862	CbGeAlD
Aripiprazole—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000596	0.00847	CbGeAlD
Aripiprazole—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000584	0.0083	CbGeAlD
Aripiprazole—DRD3—nervous system—acquired immunodeficiency syndrome	0.000564	0.00802	CbGeAlD
Aripiprazole—DRD3—central nervous system—acquired immunodeficiency syndrome	0.000543	0.00772	CbGeAlD
Aripiprazole—HTR6—nervous system—acquired immunodeficiency syndrome	0.000543	0.00772	CbGeAlD
Aripiprazole—H1F0—lymphoid tissue—acquired immunodeficiency syndrome	0.000536	0.00761	CbGeAlD
Aripiprazole—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000529	0.00752	CbGeAlD
Aripiprazole—HTR1E—brain—acquired immunodeficiency syndrome	0.000529	0.00752	CbGeAlD
Aripiprazole—H1F0—digestive system—acquired immunodeficiency syndrome	0.000529	0.00752	CbGeAlD
Aripiprazole—DRD5—nervous system—acquired immunodeficiency syndrome	0.000529	0.00751	CbGeAlD
Aripiprazole—HTR6—central nervous system—acquired immunodeficiency syndrome	0.000523	0.00743	CbGeAlD
Aripiprazole—DRD5—central nervous system—acquired immunodeficiency syndrome	0.000509	0.00723	CbGeAlD
Aripiprazole—HTR3A—digestive system—acquired immunodeficiency syndrome	0.000505	0.00717	CbGeAlD
Aripiprazole—H1F0—blood—acquired immunodeficiency syndrome	0.000504	0.00716	CbGeAlD
Aripiprazole—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00049	0.00696	CbGeAlD
Aripiprazole—H1F0—bone marrow—acquired immunodeficiency syndrome	0.000488	0.00693	CbGeAlD
Aripiprazole—H1F0—spinal cord—acquired immunodeficiency syndrome	0.000486	0.0069	CbGeAlD
Aripiprazole—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000482	0.00685	CbGeAlD
Aripiprazole—HTR3A—blood—acquired immunodeficiency syndrome	0.000481	0.00683	CbGeAlD
Aripiprazole—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000477	0.00677	CbGeAlD
Aripiprazole—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000474	0.00674	CbGeAlD
Aripiprazole—H1F0—vagina—acquired immunodeficiency syndrome	0.000467	0.00664	CbGeAlD
Aripiprazole—CHRM4—brain—acquired immunodeficiency syndrome	0.000464	0.00659	CbGeAlD
Aripiprazole—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000457	0.00649	CbGeAlD
Aripiprazole—H1F0—lung—acquired immunodeficiency syndrome	0.000442	0.00628	CbGeAlD
Aripiprazole—DRD2—retina—acquired immunodeficiency syndrome	0.00044	0.00625	CbGeAlD
Aripiprazole—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.000433	0.00616	CbGeAlD
Aripiprazole—DRD3—brain—acquired immunodeficiency syndrome	0.000431	0.00613	CbGeAlD
Aripiprazole—HTR3A—lung—acquired immunodeficiency syndrome	0.000421	0.00599	CbGeAlD
Aripiprazole—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.000417	0.00593	CbGeAlD
Aripiprazole—HTR6—brain—acquired immunodeficiency syndrome	0.000415	0.0059	CbGeAlD
Aripiprazole—H1F0—nervous system—acquired immunodeficiency syndrome	0.000409	0.00581	CbGeAlD
Aripiprazole—DRD5—brain—acquired immunodeficiency syndrome	0.000404	0.00574	CbGeAlD
Aripiprazole—DRD1—nervous system—acquired immunodeficiency syndrome	0.000404	0.00574	CbGeAlD
Aripiprazole—H1F0—central nervous system—acquired immunodeficiency syndrome	0.000394	0.0056	CbGeAlD
Aripiprazole—HTR3A—nervous system—acquired immunodeficiency syndrome	0.00039	0.00554	CbGeAlD
Aripiprazole—DRD1—central nervous system—acquired immunodeficiency syndrome	0.000389	0.00553	CbGeAlD
Aripiprazole—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000389	0.00552	CbGeAlD
Aripiprazole—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000385	0.00547	CbGeAlD
Aripiprazole—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000381	0.00542	CbGeAlD
Aripiprazole—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000376	0.00534	CbGeAlD
Aripiprazole—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000372	0.00529	CbGeAlD
Aripiprazole—SLC6A4—blood—acquired immunodeficiency syndrome	0.000367	0.00521	CbGeAlD
Aripiprazole—HTR2B—blood—acquired immunodeficiency syndrome	0.000363	0.00516	CbGeAlD
Aripiprazole—CHRM5—brain—acquired immunodeficiency syndrome	0.000363	0.00515	CbGeAlD
Aripiprazole—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000353	0.00502	CbGeAlD
Aripiprazole—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000347	0.00493	CbGeAlD
Aripiprazole—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000343	0.00487	CbGeAlD
Aripiprazole—HTR2B—vagina—acquired immunodeficiency syndrome	0.000337	0.00478	CbGeAlD
Aripiprazole—ADRB1—lung—acquired immunodeficiency syndrome	0.000333	0.00473	CbGeAlD
Aripiprazole—ADRA1B—brain—acquired immunodeficiency syndrome	0.000331	0.00471	CbGeAlD
Aripiprazole—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000327	0.00465	CbGeAlD
Aripiprazole—HTR7—digestive system—acquired immunodeficiency syndrome	0.000326	0.00464	CbGeAlD
Aripiprazole—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000326	0.00463	CbGeAlD
Aripiprazole—SLC6A4—lung—acquired immunodeficiency syndrome	0.000321	0.00457	CbGeAlD
Aripiprazole—CHRM1—lung—acquired immunodeficiency syndrome	0.00032	0.00455	CbGeAlD
Aripiprazole—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000319	0.00453	CbGeAlD
Aripiprazole—HTR2B—lung—acquired immunodeficiency syndrome	0.000318	0.00452	CbGeAlD
Aripiprazole—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000317	0.0045	CbGeAlD
Aripiprazole—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000315	0.00448	CbGeAlD
Aripiprazole—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000314	0.00446	CbGeAlD
Aripiprazole—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000314	0.00445	CbGeAlD
Aripiprazole—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000314	0.00445	CbGeAlD
Aripiprazole—H1F0—brain—acquired immunodeficiency syndrome	0.000313	0.00444	CbGeAlD
Aripiprazole—HTR7—blood—acquired immunodeficiency syndrome	0.000311	0.00442	CbGeAlD
Aripiprazole—DRD1—brain—acquired immunodeficiency syndrome	0.000309	0.00439	CbGeAlD
Aripiprazole—ADRB1—nervous system—acquired immunodeficiency syndrome	0.000308	0.00438	CbGeAlD
Aripiprazole—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000305	0.00434	CbGeAlD
Aripiprazole—H1F0—lymph node—acquired immunodeficiency syndrome	0.000302	0.00429	CbGeAlD
Aripiprazole—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000302	0.00429	CbGeAlD
Aripiprazole—ADRA1A—blood—acquired immunodeficiency syndrome	0.0003	0.00426	CbGeAlD
Aripiprazole—HTR7—spinal cord—acquired immunodeficiency syndrome	0.0003	0.00426	CbGeAlD
Aripiprazole—HTR3A—brain—acquired immunodeficiency syndrome	0.000298	0.00424	CbGeAlD
Aripiprazole—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000298	0.00423	CbGeAlD
Aripiprazole—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.000297	0.00421	CbGeAlD
Aripiprazole—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000296	0.00421	CbGeAlD
Aripiprazole—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000295	0.00419	CbGeAlD
Aripiprazole—HTR2A—retina—acquired immunodeficiency syndrome	0.00029	0.00412	CbGeAlD
Aripiprazole—KCNH2—blood—acquired immunodeficiency syndrome	0.00029	0.00412	CbGeAlD
Aripiprazole—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000286	0.00407	CbGeAlD
Aripiprazole—ADRA2C—blood—acquired immunodeficiency syndrome	0.000286	0.00406	CbGeAlD
Aripiprazole—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000285	0.00405	CbGeAlD
Aripiprazole—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000284	0.00403	CbGeAlD
Aripiprazole—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.00028	0.00398	CbGeAlD
Aripiprazole—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000279	0.00397	CbGeAlD
Aripiprazole—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000275	0.00391	CbGeAlD
Aripiprazole—HTR7—lung—acquired immunodeficiency syndrome	0.000273	0.00387	CbGeAlD
Aripiprazole—KCNH2—vagina—acquired immunodeficiency syndrome	0.000269	0.00382	CbGeAlD
Aripiprazole—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000265	0.00377	CbGeAlD
Aripiprazole—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000265	0.00376	CbGeAlD
Aripiprazole—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000264	0.00375	CbGeAlD
Aripiprazole—DRD2—lung—acquired immunodeficiency syndrome	0.000258	0.00366	CbGeAlD
Aripiprazole—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000255	0.00363	CbGeAlD
Aripiprazole—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000254	0.00361	CbGeAlD
Aripiprazole—HTR7—nervous system—acquired immunodeficiency syndrome	0.000252	0.00359	CbGeAlD
Aripiprazole—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000251	0.00357	CbGeAlD
Aripiprazole—ADRA2C—lung—acquired immunodeficiency syndrome	0.000251	0.00356	CbGeAlD
Aripiprazole—HTR1B—brain—acquired immunodeficiency syndrome	0.00025	0.00356	CbGeAlD
Aripiprazole—CHRM2—brain—acquired immunodeficiency syndrome	0.000249	0.00354	CbGeAlD
Aripiprazole—HRH1—digestive system—acquired immunodeficiency syndrome	0.000244	0.00346	CbGeAlD
Aripiprazole—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000244	0.00346	CbGeAlD
Aripiprazole—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000243	0.00345	CbGeAlD
Aripiprazole—HTR1D—brain—acquired immunodeficiency syndrome	0.000242	0.00344	CbGeAlD
Aripiprazole—HTR2C—brain—acquired immunodeficiency syndrome	0.00024	0.00341	CbGeAlD
Aripiprazole—CYP3A5—blood—acquired immunodeficiency syndrome	0.000239	0.0034	CbGeAlD
Aripiprazole—DRD2—nervous system—acquired immunodeficiency syndrome	0.000239	0.00339	CbGeAlD
Aripiprazole—ADRB1—brain—acquired immunodeficiency syndrome	0.000235	0.00334	CbGeAlD
Aripiprazole—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000235	0.00334	CbGeAlD
Aripiprazole—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000234	0.00333	CbGeAlD
Aripiprazole—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000232	0.0033	CbGeAlD
Aripiprazole—DRD2—central nervous system—acquired immunodeficiency syndrome	0.00023	0.00327	CbGeAlD
Aripiprazole—ADRA2A—blood—acquired immunodeficiency syndrome	0.000228	0.00324	CbGeAlD
Aripiprazole—SLC6A4—brain—acquired immunodeficiency syndrome	0.000227	0.00323	CbGeAlD
Aripiprazole—CHRM1—brain—acquired immunodeficiency syndrome	0.000227	0.00322	CbGeAlD
Aripiprazole—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000226	0.00322	CbGeAlD
Aripiprazole—HTR2B—brain—acquired immunodeficiency syndrome	0.000225	0.0032	CbGeAlD
Aripiprazole—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000223	0.00317	CbGeAlD
Aripiprazole—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000222	0.00315	CbGeAlD
Aripiprazole—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.00022	0.00312	CbGeAlD
Aripiprazole—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000218	0.00309	CbGeAlD
Aripiprazole—HRH1—vagina—acquired immunodeficiency syndrome	0.000215	0.00306	CbGeAlD
Aripiprazole—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000211	0.003	CbGeAlD
Aripiprazole—CYP3A5—lung—acquired immunodeficiency syndrome	0.00021	0.00298	CbGeAlD
Aripiprazole—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000204	0.00289	CbGeAlD
Aripiprazole—HRH1—lung—acquired immunodeficiency syndrome	0.000204	0.00289	CbGeAlD
Aripiprazole—CHRM3—brain—acquired immunodeficiency syndrome	0.000203	0.00288	CbGeAlD
Aripiprazole—HTR1A—brain—acquired immunodeficiency syndrome	0.000202	0.00287	CbGeAlD
Aripiprazole—ADRA2A—lung—acquired immunodeficiency syndrome	0.0002	0.00284	CbGeAlD
Aripiprazole—HTR2A—blood—acquired immunodeficiency syndrome	0.000194	0.00276	CbGeAlD
Aripiprazole—HTR7—brain—acquired immunodeficiency syndrome	0.000193	0.00274	CbGeAlD
Aripiprazole—ABCB1—retina—acquired immunodeficiency syndrome	0.00019	0.0027	CbGeAlD
Aripiprazole—HRH1—nervous system—acquired immunodeficiency syndrome	0.000189	0.00268	CbGeAlD
Aripiprazole—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000188	0.00268	CbGeAlD
Aripiprazole—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000187	0.00265	CbGeAlD
Aripiprazole—ADRA1A—brain—acquired immunodeficiency syndrome	0.000186	0.00264	CbGeAlD
Aripiprazole—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000185	0.00264	CbGeAlD
Aripiprazole—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000185	0.00263	CbGeAlD
Aripiprazole—DRD2—brain—acquired immunodeficiency syndrome	0.000182	0.00259	CbGeAlD
Aripiprazole—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000181	0.00258	CbGeAlD
Aripiprazole—HTR2A—vagina—acquired immunodeficiency syndrome	0.00018	0.00255	CbGeAlD
Aripiprazole—KCNH2—brain—acquired immunodeficiency syndrome	0.00018	0.00255	CbGeAlD
Aripiprazole—CYP3A4—blood—acquired immunodeficiency syndrome	0.00018	0.00255	CbGeAlD
Aripiprazole—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000178	0.00253	CbGeAlD
Aripiprazole—ADRA2C—brain—acquired immunodeficiency syndrome	0.000177	0.00252	CbGeAlD
Aripiprazole—CYP2D6—blood—acquired immunodeficiency syndrome	0.000177	0.00251	CbGeAlD
Aripiprazole—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000174	0.00247	CbGeAlD
Aripiprazole—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000171	0.00244	CbGeAlD
Aripiprazole—HTR2A—lung—acquired immunodeficiency syndrome	0.00017	0.00242	CbGeAlD
Aripiprazole—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000157	0.00224	CbGeAlD
Aripiprazole—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000152	0.00215	CbGeAlD
Aripiprazole—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000146	0.00207	CbGeAlD
Aripiprazole—HRH1—brain—acquired immunodeficiency syndrome	0.000144	0.00205	CbGeAlD
Aripiprazole—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000143	0.00204	CbGeAlD
Aripiprazole—ADRA2A—brain—acquired immunodeficiency syndrome	0.000142	0.00201	CbGeAlD
Aripiprazole—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.00014	0.00199	CbGeAlD
Aripiprazole—HRH1—lymph node—acquired immunodeficiency syndrome	0.000139	0.00198	CbGeAlD
Aripiprazole—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000138	0.00196	CbGeAlD
Aripiprazole—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000137	0.00194	CbGeAlD
Aripiprazole—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000135	0.00192	CbGeAlD
Aripiprazole—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000133	0.0019	CbGeAlD
Aripiprazole—ABCB1—blood—acquired immunodeficiency syndrome	0.000127	0.00181	CbGeAlD
Aripiprazole—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000123	0.00175	CbGeAlD
Aripiprazole—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000122	0.00174	CbGeAlD
Aripiprazole—HTR2A—brain—acquired immunodeficiency syndrome	0.00012	0.00171	CbGeAlD
Aripiprazole—ABCB1—vagina—acquired immunodeficiency syndrome	0.000118	0.00167	CbGeAlD
Aripiprazole—ABCB1—lung—acquired immunodeficiency syndrome	0.000111	0.00158	CbGeAlD
Aripiprazole—CYP2D6—brain—acquired immunodeficiency syndrome	0.00011	0.00156	CbGeAlD
Aripiprazole—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000103	0.00147	CbGeAlD
Aripiprazole—ABCB1—central nervous system—acquired immunodeficiency syndrome	9.93e-05	0.00141	CbGeAlD
Aripiprazole—ABCB1—brain—acquired immunodeficiency syndrome	7.89e-05	0.00112	CbGeAlD
Aripiprazole—ABCB1—lymph node—acquired immunodeficiency syndrome	7.62e-05	0.00108	CbGeAlD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	5.64e-05	0.000213	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	5.62e-05	0.000212	CcSEcCtD
Aripiprazole—Pruritus—Abacavir—acquired immunodeficiency syndrome	5.61e-05	0.000212	CcSEcCtD
Aripiprazole—Fatigue—Indinavir—acquired immunodeficiency syndrome	5.61e-05	0.000212	CcSEcCtD
Aripiprazole—Anorexia—Delavirdine—acquired immunodeficiency syndrome	5.61e-05	0.000212	CcSEcCtD
Aripiprazole—Discomfort—Ritonavir—acquired immunodeficiency syndrome	5.61e-05	0.000212	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	5.6e-05	0.000211	CcSEcCtD
Aripiprazole—Cough—Saquinavir—acquired immunodeficiency syndrome	5.6e-05	0.000211	CcSEcCtD
Aripiprazole—Angioedema—Lamivudine—acquired immunodeficiency syndrome	5.59e-05	0.000211	CcSEcCtD
Aripiprazole—Pain—Indinavir—acquired immunodeficiency syndrome	5.57e-05	0.00021	CcSEcCtD
Aripiprazole—Constipation—Indinavir—acquired immunodeficiency syndrome	5.57e-05	0.00021	CcSEcCtD
Aripiprazole—Insomnia—Efavirenz—acquired immunodeficiency syndrome	5.56e-05	0.00021	CcSEcCtD
Aripiprazole—Urticaria—Zidovudine—acquired immunodeficiency syndrome	5.56e-05	0.00021	CcSEcCtD
Aripiprazole—Convulsion—Saquinavir—acquired immunodeficiency syndrome	5.56e-05	0.00021	CcSEcCtD
Aripiprazole—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	5.55e-05	0.000209	CcSEcCtD
Aripiprazole—Hypertension—Saquinavir—acquired immunodeficiency syndrome	5.54e-05	0.000209	CcSEcCtD
Aripiprazole—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.53e-05	0.000209	CcSEcCtD
Aripiprazole—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.53e-05	0.000209	CcSEcCtD
Aripiprazole—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.53e-05	0.000208	CcSEcCtD
Aripiprazole—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	5.52e-05	0.000208	CcSEcCtD
Aripiprazole—Malaise—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.000208	CcSEcCtD
Aripiprazole—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.51e-05	0.000208	CcSEcCtD
Aripiprazole—Nausea—Didanosine—acquired immunodeficiency syndrome	5.51e-05	0.000208	CcSEcCtD
Aripiprazole—Vertigo—Lamivudine—acquired immunodeficiency syndrome	5.5e-05	0.000207	CcSEcCtD
Aripiprazole—Hypotension—Delavirdine—acquired immunodeficiency syndrome	5.5e-05	0.000207	CcSEcCtD
Aripiprazole—Syncope—Lamivudine—acquired immunodeficiency syndrome	5.49e-05	0.000207	CcSEcCtD
Aripiprazole—Confusional state—Ritonavir—acquired immunodeficiency syndrome	5.49e-05	0.000207	CcSEcCtD
Aripiprazole—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	5.48e-05	0.000207	CcSEcCtD
Aripiprazole—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.48e-05	0.000207	CcSEcCtD
Aripiprazole—Somnolence—Efavirenz—acquired immunodeficiency syndrome	5.47e-05	0.000206	CcSEcCtD
Aripiprazole—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	5.46e-05	0.000206	CcSEcCtD
Aripiprazole—Chest pain—Saquinavir—acquired immunodeficiency syndrome	5.46e-05	0.000206	CcSEcCtD
Aripiprazole—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5.46e-05	0.000206	CcSEcCtD
Aripiprazole—Anxiety—Saquinavir—acquired immunodeficiency syndrome	5.44e-05	0.000205	CcSEcCtD
Aripiprazole—Oedema—Ritonavir—acquired immunodeficiency syndrome	5.44e-05	0.000205	CcSEcCtD
Aripiprazole—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.43e-05	0.000205	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.43e-05	0.000205	CcSEcCtD
Aripiprazole—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	5.41e-05	0.000204	CcSEcCtD
Aripiprazole—Discomfort—Saquinavir—acquired immunodeficiency syndrome	5.4e-05	0.000204	CcSEcCtD
Aripiprazole—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.38e-05	0.000203	CcSEcCtD
Aripiprazole—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	5.36e-05	0.000202	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.36e-05	0.000202	CcSEcCtD
Aripiprazole—Shock—Ritonavir—acquired immunodeficiency syndrome	5.35e-05	0.000202	CcSEcCtD
Aripiprazole—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.35e-05	0.000202	CcSEcCtD
Aripiprazole—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.34e-05	0.000202	CcSEcCtD
Aripiprazole—Cough—Lamivudine—acquired immunodeficiency syndrome	5.34e-05	0.000202	CcSEcCtD
Aripiprazole—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.34e-05	0.000202	CcSEcCtD
Aripiprazole—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.34e-05	0.000201	CcSEcCtD
Aripiprazole—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.33e-05	0.000201	CcSEcCtD
Aripiprazole—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.33e-05	0.000201	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.32e-05	0.000201	CcSEcCtD
Aripiprazole—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.32e-05	0.000201	CcSEcCtD
Aripiprazole—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.31e-05	0.0002	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.31e-05	0.0002	CcSEcCtD
Aripiprazole—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.0002	CcSEcCtD
Aripiprazole—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.3e-05	0.0002	CcSEcCtD
Aripiprazole—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.3e-05	0.0002	CcSEcCtD
Aripiprazole—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.29e-05	0.000199	CcSEcCtD
Aripiprazole—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.28e-05	0.000199	CcSEcCtD
Aripiprazole—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.28e-05	0.000199	CcSEcCtD
Aripiprazole—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.000198	CcSEcCtD
Aripiprazole—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.26e-05	0.000198	CcSEcCtD
Aripiprazole—Pain—Efavirenz—acquired immunodeficiency syndrome	5.26e-05	0.000198	CcSEcCtD
Aripiprazole—Rash—Nevirapine—acquired immunodeficiency syndrome	5.26e-05	0.000198	CcSEcCtD
Aripiprazole—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.25e-05	0.000198	CcSEcCtD
Aripiprazole—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.25e-05	0.000198	CcSEcCtD
Aripiprazole—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.25e-05	0.000198	CcSEcCtD
Aripiprazole—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.24e-05	0.000198	CcSEcCtD
Aripiprazole—Somnolence—Delavirdine—acquired immunodeficiency syndrome	5.23e-05	0.000197	CcSEcCtD
Aripiprazole—Headache—Nevirapine—acquired immunodeficiency syndrome	5.23e-05	0.000197	CcSEcCtD
Aripiprazole—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000197	CcSEcCtD
Aripiprazole—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000197	CcSEcCtD
Aripiprazole—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000197	CcSEcCtD
Aripiprazole—Infection—Saquinavir—acquired immunodeficiency syndrome	5.2e-05	0.000196	CcSEcCtD
Aripiprazole—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.19e-05	0.000196	CcSEcCtD
Aripiprazole—Anorexia—Ritonavir—acquired immunodeficiency syndrome	5.19e-05	0.000196	CcSEcCtD
Aripiprazole—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5.18e-05	0.000195	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.18e-05	0.000195	CcSEcCtD
Aripiprazole—Urticaria—Indinavir—acquired immunodeficiency syndrome	5.17e-05	0.000195	CcSEcCtD
Aripiprazole—Shock—Saquinavir—acquired immunodeficiency syndrome	5.15e-05	0.000194	CcSEcCtD
Aripiprazole—Discomfort—Lamivudine—acquired immunodeficiency syndrome	5.15e-05	0.000194	CcSEcCtD
Aripiprazole—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.15e-05	0.000194	CcSEcCtD
Aripiprazole—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.15e-05	0.000194	CcSEcCtD
Aripiprazole—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.14e-05	0.000194	CcSEcCtD
Aripiprazole—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.14e-05	0.000194	CcSEcCtD
Aripiprazole—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.13e-05	0.000193	CcSEcCtD
Aripiprazole—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.12e-05	0.000193	CcSEcCtD
Aripiprazole—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.12e-05	0.000193	CcSEcCtD
Aripiprazole—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.1e-05	0.000192	CcSEcCtD
Aripiprazole—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.09e-05	0.000192	CcSEcCtD
Aripiprazole—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.09e-05	0.000192	CcSEcCtD
Aripiprazole—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.09e-05	0.000192	CcSEcCtD
Aripiprazole—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000192	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.08e-05	0.000192	CcSEcCtD
Aripiprazole—Rash—Stavudine—acquired immunodeficiency syndrome	5.08e-05	0.000192	CcSEcCtD
Aripiprazole—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.07e-05	0.000191	CcSEcCtD
Aripiprazole—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.07e-05	0.000191	CcSEcCtD
Aripiprazole—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.07e-05	0.000191	CcSEcCtD
Aripiprazole—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000191	CcSEcCtD
Aripiprazole—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.06e-05	0.000191	CcSEcCtD
Aripiprazole—Headache—Stavudine—acquired immunodeficiency syndrome	5.04e-05	0.00019	CcSEcCtD
Aripiprazole—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.04e-05	0.00019	CcSEcCtD
Aripiprazole—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.04e-05	0.00019	CcSEcCtD
Aripiprazole—Pain—Delavirdine—acquired immunodeficiency syndrome	5.03e-05	0.00019	CcSEcCtD
Aripiprazole—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.03e-05	0.00019	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.03e-05	0.00019	CcSEcCtD
Aripiprazole—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.02e-05	0.000189	CcSEcCtD
Aripiprazole—Rash—Abacavir—acquired immunodeficiency syndrome	5e-05	0.000189	CcSEcCtD
Aripiprazole—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5e-05	0.000189	CcSEcCtD
Aripiprazole—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5e-05	0.000188	CcSEcCtD
Aripiprazole—Oedema—Lamivudine—acquired immunodeficiency syndrome	5e-05	0.000188	CcSEcCtD
Aripiprazole—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000188	CcSEcCtD
Aripiprazole—Headache—Abacavir—acquired immunodeficiency syndrome	4.97e-05	0.000187	CcSEcCtD
Aripiprazole—Infection—Lamivudine—acquired immunodeficiency syndrome	4.96e-05	0.000187	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.96e-05	0.000187	CcSEcCtD
Aripiprazole—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.95e-05	0.000187	CcSEcCtD
Aripiprazole—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.95e-05	0.000187	CcSEcCtD
Aripiprazole—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.92e-05	0.000186	CcSEcCtD
Aripiprazole—Shock—Lamivudine—acquired immunodeficiency syndrome	4.92e-05	0.000185	CcSEcCtD
Aripiprazole—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4.9e-05	0.000185	CcSEcCtD
Aripiprazole—Hypotension—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000185	CcSEcCtD
Aripiprazole—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000185	CcSEcCtD
Aripiprazole—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	4.89e-05	0.000184	CcSEcCtD
Aripiprazole—Urticaria—Efavirenz—acquired immunodeficiency syndrome	4.89e-05	0.000184	CcSEcCtD
Aripiprazole—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.86e-05	0.000183	CcSEcCtD
Aripiprazole—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	4.86e-05	0.000183	CcSEcCtD
Aripiprazole—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.85e-05	0.000183	CcSEcCtD
Aripiprazole—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	4.85e-05	0.000183	CcSEcCtD
Aripiprazole—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	4.85e-05	0.000183	CcSEcCtD
Aripiprazole—Somnolence—Ritonavir—acquired immunodeficiency syndrome	4.84e-05	0.000182	CcSEcCtD
Aripiprazole—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000182	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.81e-05	0.000182	CcSEcCtD
Aripiprazole—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.8e-05	0.000181	CcSEcCtD
Aripiprazole—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	4.8e-05	0.000181	CcSEcCtD
Aripiprazole—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	4.79e-05	0.000181	CcSEcCtD
Aripiprazole—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.79e-05	0.000181	CcSEcCtD
Aripiprazole—Nausea—Stavudine—acquired immunodeficiency syndrome	4.78e-05	0.00018	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4.77e-05	0.00018	CcSEcCtD
Aripiprazole—Anorexia—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.00018	CcSEcCtD
Aripiprazole—Insomnia—Saquinavir—acquired immunodeficiency syndrome	4.74e-05	0.000179	CcSEcCtD
Aripiprazole—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	4.73e-05	0.000178	CcSEcCtD
Aripiprazole—Nausea—Abacavir—acquired immunodeficiency syndrome	4.71e-05	0.000178	CcSEcCtD
Aripiprazole—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	4.7e-05	0.000177	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.7e-05	0.000177	CcSEcCtD
Aripiprazole—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.69e-05	0.000177	CcSEcCtD
Aripiprazole—Urticaria—Delavirdine—acquired immunodeficiency syndrome	4.67e-05	0.000176	CcSEcCtD
Aripiprazole—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.67e-05	0.000176	CcSEcCtD
Aripiprazole—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	4.67e-05	0.000176	CcSEcCtD
Aripiprazole—Hypotension—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.000176	CcSEcCtD
Aripiprazole—Somnolence—Saquinavir—acquired immunodeficiency syndrome	4.66e-05	0.000176	CcSEcCtD
Aripiprazole—Pain—Ritonavir—acquired immunodeficiency syndrome	4.65e-05	0.000176	CcSEcCtD
Aripiprazole—Constipation—Ritonavir—acquired immunodeficiency syndrome	4.65e-05	0.000176	CcSEcCtD
Aripiprazole—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.65e-05	0.000175	CcSEcCtD
Aripiprazole—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	4.65e-05	0.000175	CcSEcCtD
Aripiprazole—Dizziness—Zidovudine—acquired immunodeficiency syndrome	4.63e-05	0.000175	CcSEcCtD
Aripiprazole—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	4.61e-05	0.000174	CcSEcCtD
Aripiprazole—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.61e-05	0.000174	CcSEcCtD
Aripiprazole—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.55e-05	0.000172	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.55e-05	0.000172	CcSEcCtD
Aripiprazole—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.53e-05	0.000171	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.52e-05	0.000171	CcSEcCtD
Aripiprazole—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.52e-05	0.00017	CcSEcCtD
Aripiprazole—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.52e-05	0.00017	CcSEcCtD
Aripiprazole—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.49e-05	0.000169	CcSEcCtD
Aripiprazole—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.48e-05	0.000169	CcSEcCtD
Aripiprazole—Pain—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000169	CcSEcCtD
Aripiprazole—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000169	CcSEcCtD
Aripiprazole—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.45e-05	0.000168	CcSEcCtD
Aripiprazole—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.45e-05	0.000168	CcSEcCtD
Aripiprazole—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.45e-05	0.000168	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.45e-05	0.000168	CcSEcCtD
Aripiprazole—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.44e-05	0.000168	CcSEcCtD
Aripiprazole—Rash—Zidovudine—acquired immunodeficiency syndrome	4.41e-05	0.000166	CcSEcCtD
Aripiprazole—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.41e-05	0.000166	CcSEcCtD
Aripiprazole—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.41e-05	0.000166	CcSEcCtD
Aripiprazole—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.4e-05	0.000166	CcSEcCtD
Aripiprazole—Headache—Zidovudine—acquired immunodeficiency syndrome	4.38e-05	0.000165	CcSEcCtD
Aripiprazole—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.35e-05	0.000164	CcSEcCtD
Aripiprazole—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.34e-05	0.000164	CcSEcCtD
Aripiprazole—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.34e-05	0.000164	CcSEcCtD
Aripiprazole—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.32e-05	0.000163	CcSEcCtD
Aripiprazole—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.32e-05	0.000163	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.31e-05	0.000163	CcSEcCtD
Aripiprazole—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.31e-05	0.000163	CcSEcCtD
Aripiprazole—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.3e-05	0.000162	CcSEcCtD
Aripiprazole—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.3e-05	0.000162	CcSEcCtD
Aripiprazole—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.3e-05	0.000162	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.28e-05	0.000162	CcSEcCtD
Aripiprazole—Pain—Lamivudine—acquired immunodeficiency syndrome	4.27e-05	0.000161	CcSEcCtD
Aripiprazole—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.27e-05	0.000161	CcSEcCtD
Aripiprazole—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.22e-05	0.000159	CcSEcCtD
Aripiprazole—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.21e-05	0.000159	CcSEcCtD
Aripiprazole—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.16e-05	0.000157	CcSEcCtD
Aripiprazole—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.16e-05	0.000157	CcSEcCtD
Aripiprazole—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.16e-05	0.000157	CcSEcCtD
Aripiprazole—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.14e-05	0.000156	CcSEcCtD
Aripiprazole—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.14e-05	0.000156	CcSEcCtD
Aripiprazole—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.14e-05	0.000156	CcSEcCtD
Aripiprazole—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000155	CcSEcCtD
Aripiprazole—Rash—Indinavir—acquired immunodeficiency syndrome	4.1e-05	0.000155	CcSEcCtD
Aripiprazole—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.1e-05	0.000155	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.09e-05	0.000154	CcSEcCtD
Aripiprazole—Headache—Indinavir—acquired immunodeficiency syndrome	4.08e-05	0.000154	CcSEcCtD
Aripiprazole—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.07e-05	0.000153	CcSEcCtD
Aripiprazole—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.03e-05	0.000152	CcSEcCtD
Aripiprazole—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.01e-05	0.000151	CcSEcCtD
Aripiprazole—Urticaria—Lamivudine—acquired immunodeficiency syndrome	3.97e-05	0.00015	CcSEcCtD
Aripiprazole—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.95e-05	0.000149	CcSEcCtD
Aripiprazole—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.95e-05	0.000149	CcSEcCtD
Aripiprazole—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.91e-05	0.000148	CcSEcCtD
Aripiprazole—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.9e-05	0.000147	CcSEcCtD
Aripiprazole—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.89e-05	0.000147	CcSEcCtD
Aripiprazole—Rash—Efavirenz—acquired immunodeficiency syndrome	3.88e-05	0.000146	CcSEcCtD
Aripiprazole—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.87e-05	0.000146	CcSEcCtD
Aripiprazole—Nausea—Indinavir—acquired immunodeficiency syndrome	3.87e-05	0.000146	CcSEcCtD
Aripiprazole—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.86e-05	0.000146	CcSEcCtD
Aripiprazole—Headache—Efavirenz—acquired immunodeficiency syndrome	3.85e-05	0.000145	CcSEcCtD
Aripiprazole—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.85e-05	0.000145	CcSEcCtD
Aripiprazole—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.76e-05	0.000142	CcSEcCtD
Aripiprazole—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.74e-05	0.000141	CcSEcCtD
Aripiprazole—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.72e-05	0.00014	CcSEcCtD
Aripiprazole—Rash—Delavirdine—acquired immunodeficiency syndrome	3.71e-05	0.00014	CcSEcCtD
Aripiprazole—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.71e-05	0.00014	CcSEcCtD
Aripiprazole—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.71e-05	0.00014	CcSEcCtD
Aripiprazole—Headache—Delavirdine—acquired immunodeficiency syndrome	3.69e-05	0.000139	CcSEcCtD
Aripiprazole—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.68e-05	0.000139	CcSEcCtD
Aripiprazole—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.65e-05	0.000138	CcSEcCtD
Aripiprazole—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.6e-05	0.000136	CcSEcCtD
Aripiprazole—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.58e-05	0.000135	CcSEcCtD
Aripiprazole—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.58e-05	0.000135	CcSEcCtD
Aripiprazole—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.54e-05	0.000133	CcSEcCtD
Aripiprazole—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.5e-05	0.000132	CcSEcCtD
Aripiprazole—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.46e-05	0.000131	CcSEcCtD
Aripiprazole—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.46e-05	0.000131	CcSEcCtD
Aripiprazole—Rash—Ritonavir—acquired immunodeficiency syndrome	3.43e-05	0.000129	CcSEcCtD
Aripiprazole—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.43e-05	0.000129	CcSEcCtD
Aripiprazole—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.42e-05	0.000129	CcSEcCtD
Aripiprazole—Headache—Ritonavir—acquired immunodeficiency syndrome	3.41e-05	0.000129	CcSEcCtD
Aripiprazole—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.33e-05	0.000126	CcSEcCtD
Aripiprazole—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.3e-05	0.000125	CcSEcCtD
Aripiprazole—Rash—Saquinavir—acquired immunodeficiency syndrome	3.3e-05	0.000125	CcSEcCtD
Aripiprazole—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.3e-05	0.000124	CcSEcCtD
Aripiprazole—Headache—Saquinavir—acquired immunodeficiency syndrome	3.28e-05	0.000124	CcSEcCtD
Aripiprazole—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.23e-05	0.000122	CcSEcCtD
Aripiprazole—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.18e-05	0.00012	CcSEcCtD
Aripiprazole—Rash—Lamivudine—acquired immunodeficiency syndrome	3.15e-05	0.000119	CcSEcCtD
Aripiprazole—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.15e-05	0.000119	CcSEcCtD
Aripiprazole—Headache—Lamivudine—acquired immunodeficiency syndrome	3.13e-05	0.000118	CcSEcCtD
Aripiprazole—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.11e-05	0.000117	CcSEcCtD
Aripiprazole—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.97e-05	0.000112	CcSEcCtD
Aripiprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.24e-05	0.000174	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.24e-05	0.000174	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.24e-05	0.000173	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.24e-05	0.000173	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000173	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000173	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.23e-05	0.000173	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.23e-05	0.000173	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.23e-05	0.000172	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.23e-05	0.000172	CbGpPWpGaD
Aripiprazole—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.23e-05	0.000172	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.23e-05	0.000172	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000172	CbGpPWpGaD
Aripiprazole—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.23e-05	0.000172	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.22e-05	0.000172	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.000172	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.22e-05	0.000172	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.000172	CbGpPWpGaD
Aripiprazole—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000171	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.00017	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.21e-05	0.00017	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.00017	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.000169	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.19e-05	0.000167	CbGpPWpGaD
Aripiprazole—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.19e-05	0.000167	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.000167	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.19e-05	0.000167	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.19e-05	0.000167	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.000165	CbGpPWpGaD
Aripiprazole—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000165	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.17e-05	0.000165	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.17e-05	0.000164	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.17e-05	0.000164	CbGpPWpGaD
Aripiprazole—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000162	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.000162	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.15e-05	0.000161	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.14e-05	0.00016	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.14e-05	0.00016	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.14e-05	0.00016	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.14e-05	0.00016	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.14e-05	0.00016	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.13e-05	0.000159	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.13e-05	0.000159	CbGpPWpGaD
Aripiprazole—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000159	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.13e-05	0.000158	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.13e-05	0.000158	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.13e-05	0.000158	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.12e-05	0.000157	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.12e-05	0.000157	CbGpPWpGaD
Aripiprazole—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000157	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000156	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000156	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.11e-05	0.000156	CbGpPWpGaD
Aripiprazole—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000156	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.11e-05	0.000155	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.11e-05	0.000155	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000155	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.000153	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.09e-05	0.000153	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.08e-05	0.000152	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.08e-05	0.000152	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.08e-05	0.000152	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.000151	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.07e-05	0.000151	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.07e-05	0.00015	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.07e-05	0.00015	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.06e-05	0.000149	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.06e-05	0.000149	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.06e-05	0.000149	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.06e-05	0.000149	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.000148	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.06e-05	0.000148	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.06e-05	0.000148	CbGpPWpGaD
Aripiprazole—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.06e-05	0.000148	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.05e-05	0.000148	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.05e-05	0.000148	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000148	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.04e-05	0.000146	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.04e-05	0.000146	CbGpPWpGaD
Aripiprazole—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000146	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.04e-05	0.000146	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.04e-05	0.000146	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.04e-05	0.000146	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.000144	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.03e-05	0.000144	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000143	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000141	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.81e-06	0.000138	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.79e-06	0.000137	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.7e-06	0.000136	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.68e-06	0.000136	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.68e-06	0.000136	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.68e-06	0.000136	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.65e-06	0.000135	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.64e-06	0.000135	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.6e-06	0.000135	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.59e-06	0.000135	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.56e-06	0.000134	CbGpPWpGaD
Aripiprazole—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.5e-06	0.000133	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.47e-06	0.000133	CbGpPWpGaD
Aripiprazole—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.42e-06	0.000132	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.37e-06	0.000131	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.32e-06	0.000131	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.23e-06	0.000129	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.18e-06	0.000129	CbGpPWpGaD
Aripiprazole—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.09e-06	0.000127	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.06e-06	0.000127	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.04e-06	0.000127	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.93e-06	0.000125	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.92e-06	0.000125	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.82e-06	0.000124	CbGpPWpGaD
Aripiprazole—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.8e-06	0.000123	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.79e-06	0.000123	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.74e-06	0.000123	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.66e-06	0.000121	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.63e-06	0.000121	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.55e-06	0.00012	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.53e-06	0.00012	CbGpPWpGaD
Aripiprazole—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.49e-06	0.000119	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.44e-06	0.000118	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.4e-06	0.000118	CbGpPWpGaD
Aripiprazole—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.34e-06	0.000117	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.25e-06	0.000116	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.22e-06	0.000115	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.21e-06	0.000115	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.17e-06	0.000115	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.1e-06	0.000114	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.09e-06	0.000114	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.08e-06	0.000113	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.05e-06	0.000113	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.04e-06	0.000113	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.02e-06	0.000113	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.99e-06	0.000112	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.98e-06	0.000112	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.97e-06	0.000112	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.95e-06	0.000112	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.95e-06	0.000111	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.93e-06	0.000111	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.92e-06	0.000111	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.9e-06	0.000111	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.86e-06	0.00011	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.85e-06	0.00011	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.84e-06	0.00011	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.83e-06	0.00011	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.81e-06	0.00011	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.81e-06	0.000109	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.79e-06	0.000109	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.71e-06	0.000108	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.69e-06	0.000108	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.41e-06	0.000104	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.36e-06	0.000103	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.29e-06	0.000102	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.27e-06	0.000102	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.25e-06	0.000102	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.25e-06	0.000102	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.25e-06	0.000102	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.23e-06	0.000101	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	7.17e-06	0.0001	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.16e-06	0.0001	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.14e-06	0.0001	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.14e-06	0.0001	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.13e-06	0.0001	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.12e-06	9.98e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.09e-06	9.95e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.07e-06	9.92e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7e-06	9.82e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.98e-06	9.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	6.96e-06	9.76e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.63e-06	9.3e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.59e-06	9.24e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.58e-06	9.23e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.55e-06	9.19e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.55e-06	9.18e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.54e-06	9.17e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.5e-06	9.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.49e-06	9.1e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.4e-06	8.98e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.37e-06	8.93e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.3e-06	8.83e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.27e-06	8.79e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.21e-06	8.72e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.18e-06	8.67e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	6.16e-06	8.64e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.01e-06	8.43e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.98e-06	8.39e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.95e-06	8.35e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.92e-06	8.3e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.67e-06	7.95e-05	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.67e-06	7.95e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	5.65e-06	7.93e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.64e-06	7.91e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.59e-06	7.85e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.57e-06	7.81e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	5.18e-06	7.26e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.1e-06	7.15e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.07e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.05e-06	7.08e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.03e-06	7.05e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.02e-06	7.04e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.88e-06	6.84e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.85e-06	6.8e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.85e-06	6.8e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.83e-06	6.77e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.72e-06	6.62e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.69e-06	6.58e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.64e-06	6.51e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.62e-06	6.48e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.28e-06	6e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.26e-06	5.97e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.21e-06	5.91e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.2e-06	5.9e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.19e-06	5.88e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.19e-06	5.88e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.18e-06	5.87e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.18e-06	5.86e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.17e-06	5.85e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.16e-06	5.83e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.14e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.12e-06	5.79e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.12e-06	5.77e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.1e-06	5.76e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	3.91e-06	5.48e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.87e-06	5.43e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.87e-06	5.42e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.84e-06	5.39e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.83e-06	5.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.81e-06	5.35e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.76e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.7e-06	5.19e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.68e-06	5.17e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.65e-06	5.12e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.53e-06	4.96e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.5e-06	4.91e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.33e-06	4.67e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.29e-06	4.61e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3e-06	4.2e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.97e-06	4.16e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.87e-06	4.02e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.85e-06	4e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.77e-06	3.89e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.73e-06	3.83e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.52e-06	3.53e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.48e-06	3.47e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.47e-06	3.47e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.46e-06	3.45e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.45e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.43e-06	3.41e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.42e-06	3.4e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.41e-06	3.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.25e-06	3.16e-05	CbGpPWpGaD
